Paterson, RW;
Toombs, J;
Chapman, MD;
Nicholas, JM;
Heslegrave, AJ;
Slattery, CF;
Foulkes, AJM;
... Schott, JM; + view all
(2015)
Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
, 1
(3)
pp. 380-384.
10.1016/j.dadm.2015.06.003.
Preview |
Text
1-s2.0-S0022169416000172-main.pdf - Published Version Download (3MB) | Preview |
Abstract
© 2015 The Authors. Introduction: Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to support a diagnosis of Alzheimer's disease. Several preanalytical factors may alter the CSF concentrations of amyloid β 1-42 (Aβ1-42) in particular with the potential to influence diagnosis. We aimed to determine whether routine handling of samples alters measured biomarker concentration compared with that of prompt delivery to the laboratory. Methods: Forty individuals with suspected neurodegenerative diseases underwent diagnostic lumbar punctures using a standardized technique. A sample of each patient's CSF was sent to the laboratory by four different delivery methods: (1) by courier at room temperature; (2) by courier, on ice; (3) using standard hospital portering; and (4) after quarantining for >24 hours. Aβ1-42, total tau (t-tau), and phosphorylated tau (p-tau) levels measured using standard enzyme-linked immunosorbent assay techniques were compared between transfer methods. Results: There were no significant differences in Aβ1-42, t-tau, or p-tau concentrations measured in samples transported via the different delivery methods despite significant differences in time taken to deliver samples. Discussion: When CSF is collected in appropriate tubes, transferred at room temperature, and processed within 24 hours, neurodegenerative markers can be reliably determined.
Archive Staff Only
 |
View Item |
